Brian Elsbernd - 03 Sep 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Compliance/Legal Officer
Signature
/s/ Brian Elsbernd
Issuer symbol
CPRX
Transactions as of
03 Sep 2025
Net transactions value
-$875,200
Form type
4
Filing time
05 Sep 2025, 17:00:15 UTC
Previous filing
05 Mar 2025
Next filing
10 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Elsbernd Brian Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Brian Elsbernd 05 Sep 2025 0001763511

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $44,800 +20,000 +11% $2.24 208,564 03 Sep 2025 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $401,600 -20,000 -9.6% $20.08 188,564 03 Sep 2025 Direct F1, F2
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $67,200 +30,000 +16% $2.24 218,564 04 Sep 2025 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $585,600 -30,000 -14% $19.52 188,564 04 Sep 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -20,000 -2% $0.000000 989,084 03 Sep 2025 Common Stock 20,000 $2.24 Direct F4
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -30,000 -3% $0.000000 959,084 04 Sep 2025 Common Stock 30,000 $2.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold on the open market for personal reasons and not as a result of a disagreement with the Company.
F2 Represents a weighted average price for the shares sold. Shares were sold in a range from $20.035 to $20.13 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in a range from $19.325 to $19.73 per share.
F4 Options vested in three annual tranches beginning on December 19, 2019.